HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 03, March 2019 – Driven by curiosity — Exclusive interview with Nobel laureate Ada Yonath: Her journey in science wasn't always crystal clear       » Your eyes don't deceive you, your brain does       » Organ donations to be computerised in China       » Over One tenth of Chinese people have mental health problems       » AI system can diagnose childhood diseases like doctors       » Bitter rapeseed potential protein source for human nutrition      
EYE ON CHINA
Hong Kong scientists discover deadly brain cancer mutation route
Can help predict cancer cells' future behavior and prioritise treatment options

The mutational mechanism of a rare and deadly brain cancer has been uncovered by scientists from the Hong Kong University of Science and Technology, providing new therapeutic lead to the disease.

Starting off at nerve cells around the spine and brain, lower-grade glioma (LGG) is the early form of secondary glioblastoma (sGBM) -- one of the deadliest brain cancers. While sGBM can be treated with surgery or an oral chemotherapy drug, most of these malign tumors would mutate and return with mortality rate reaching almost 100 percent.

In the latest study, the team led by Wang Jiguang, assistant professor at the university's Division of Life Science and Department of Chemical and Biological Engineering, analysed and integrated the genomic data of 188 sGBM patients, including newly collected samples from Chinese mainland and South Korean patients.

The study found that about 14 percent of the sampled sGBM patients displayed mutations in this gene.

Taking reference from this discovery, the university's collaborators, Jiang Tao and his team from Beijing Neurosurgical Institute and Beijing Tiantan Hospital, identified a drug molecule named PLB-1001 that can reach the tumours in the brain.

The molecule shows remarkable potency in selectively targeting sGBM tumours and those displaying further gene mutations.

The clinical trial of PLB-1001 on 18 recurrent patients at late cancer stage returned with a partial positive response in two patients.

After being prescribed a daily dosage ranging from 50 to 300 mg at Beijing Tiantan Hospital, the two patients experienced significant tumour shrinkage, with relieved symptoms and lesser side effects, lasting for more than 12 weeks.

The outcome of this clinical trial is significant in that it furthers the knowledge about sGBM treatment, Wang said, adding that developing computational models on cancer evolution helps predict cancer cells' future behavior and prioritise treatment options.

Wang said more studies on PLB-1001 are needed to see if it can be used in conjunction with other drugs in achieving more persistent results.

The findings were published in Cell.

Source: Xinhua

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy